Participant flow

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM · Source last updated 2026-06-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 0.5 mg/kg belantamab mafodotin intravenous (IV) infusion as powder for solution once every 4 weeks (Q4W) infused over 30- 60 minutes on day 1 of each 28-day cycle in combination with 100 mg Nirogacestat administered orally twice a day (BID) up to Day 28. Along with 4 mg Pomalidomide orally per day (QD) on Days 1-21 of each 28-day cycle and Dexamethasone 40mg (20 mg for participants \>75 years old or BMI \<18.5 kg/m\^2) administered orally on days 1, 8, 15 and 22 of each 28-day cycle.

   id

   FG000

   title

   0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Ongoing at the time of analysis

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         14

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         14

      comment

      Pharmacokinetic (PK) population included all participants in the safety population from whom at least one PK sample has been obtained and analyzed.

      type

      Pharmacokinetic Population

   3. achievements

      1. group Id

         FG000

         num Subjects

         14

      comment

      Safety population included all participants who received at least one dose of any component of the combination therapy.

      type

      Safety Population

   4. achievements

      1. group Id

         FG000

         num Subjects

         11

      comment

      DLT Evaluable Population included participants in DE Phase who have received at least 80% of all components of the intended dose of treatment in cycle 1 and were followed up for a period of one cycle length or withdrawn within the first cycle due to an AE meeting the definition of a DLT.

      type

      DLT Evaluable Population

   5. achievements

      1. comment

         4 participants completed the follow-up and 3 participants died.

         group Id

         FG000

         num Subjects

         7

      comment

      Participants who completed follow-up or who died were considered to have completed the study.

      type

      COMPLETED

   6. achievements

      1. group Id

         FG000

         num Subjects

         7

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

The results presented are based on the data cut-off date of 17 Apr 2025. Those participants still benefiting from study drug in the opinion of their treating physician continued to receive study drug in Post Analysis Continuation of Treatment (PACT) phase and their safety data will be provided within a year of study completion.

recruitment Details

This is a sub-study of the master study NCT04126200. The study was planned to include two phases - Dose Escalation (DE) and Cohort Expansion (CE) and no participants from this sub study were enrolled in CE phase as CE Phase was not initiated due to business strategic reason.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice